Metabolomic and Lipidomic Signatures in Autosomal Dominant and Late-onset Alzheimer's Disease Brains

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2022 Oct 17

PMID 36251323

Authors

Brenna C Novotny

Maria Victoria Fernandez

Ciyang Wang

John P Budde

Kristy Bergmann

Abdallah M Eteleeb

Joseph Bradley

Carol Webster

Curtis Ebl

Joanne Norton

Jen Gentsch

Umber Dube

Fengxian Wang

John C Morris

Randall J Bateman

Richard J Perrin

Eric McDade

Chengjie Xiong

Jasmeer Chhatwal

Alison Goate

Martin Farlow

Peter Schofield

Helena Chui

Celeste M Karch

Carlos Cruchaga

Bruno A Benitez

Oscar Harari

Affiliations

Soon will be listed here.

Abstract

Introduction: The identification of multiple genetic risk factors for Alzheimer's disease (AD) suggests that many pathways contribute to AD onset and progression. However, the metabolomic and lipidomic profiles in carriers of distinct genetic risk factors are not fully understood. The metabolome can provide a direct image of dysregulated pathways in the brain.

Methods: We interrogated metabolomic signatures in the AD brain, including carriers of pathogenic variants in APP, PSEN1, and PSEN2 (autosomal dominant AD; ADAD), APOE ɛ4, and TREM2 risk variant carriers, and sporadic AD (sAD).

Results: We identified 133 unique and shared metabolites associated with ADAD, TREM2, and sAD. We identified a signature of 16 metabolites significantly altered between groups and associated with AD duration.

Discussion: AD genetic variants show distinct metabolic perturbations. Investigation of these metabolites may provide greater insight into the etiology of AD and its impact on clinical presentation.

Highlights: APP/PSEN1/PSEN2 and TREM2 variant carriers show distinct metabolic changes. A total of 133 metabolites were differentially abundant in AD genetic groups. β-citrylglutamate is differentially abundant in autosomal dominant, TREM2, and sporadic AD. A 16-metabolite profile shows differences between Alzheimer's disease (AD) genetic groups. The identified metabolic profile is associated with duration of disease.

Citing Articles

The blood metabolome of cognitive function and brain health in middle-aged adults - influences of genes, gut microbiome, and exposome.

Ahmad S, Wu T, Arnold M, Hankemeier T, Ghanbari M, Roshchupkin G medRxiv. 2025; .

PMID: 39763567 PMC: 11702749. DOI: 10.1101/2024.12.16.24317793.

Multiomic profiling reveals timing of menopause predicts prefrontal cortex aging and cognitive function.

Gunter-Rahman F, Adams C, Raju R, Zhang Y, Lee E, Messerlian C Aging Cell. 2024; 24(2):e14395.

PMID: 39501567 PMC: 11822667. DOI: 10.1111/acel.14395.

Correlation Between Regulation of Intestinal Flora by Danggui-Shaoyao-San and Improvement of Cognitive Impairment in Mice With Alzheimer's Disease.

Wang Y, Ding P, Zhang K, Xu X, Li H Brain Behav. 2024; 14(11):e70110.

PMID: 39482855 PMC: 11527834. DOI: 10.1002/brb3.70110.

The mTOR Pathway: A Common Link Between Alzheimer's Disease and Down Syndrome.

Wohlfert A, Phares J, Granholm A J Clin Med. 2024; 13(20).

PMID: 39458132 PMC: 11508835. DOI: 10.3390/jcm13206183.

Ergothioneine-Mediated Neuroprotection of Human iPSC-Derived Dopaminergic Neurons.

Leow D, Cheah I, Chen L, Ng Y, Yeo C, Halliwell B Antioxidants (Basel). 2024; 13(6).

PMID: 38929132 PMC: 11200999. DOI: 10.3390/antiox13060693.

References

Varma V, Oommen A, Varma S, Casanova R, An Y, Andrews R . Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med. 2018; 15(1):e1002482. PMC: 5784884. DOI: 10.1371/journal.pmed.1002482. View

Akanmu D, Cecchini R, Aruoma O, Halliwell B . The antioxidant action of ergothioneine. Arch Biochem Biophys. 1991; 288(1):10-6. DOI: 10.1016/0003-9861(91)90158-f. View

Ulland T, Colonna M . TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018; 14(11):667-675. DOI: 10.1038/s41582-018-0072-1. View

Li Z, Del-Aguila J, Dube U, Budde J, Martinez R, Black K . Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med. 2018; 10(1):43. PMC: 5992755. DOI: 10.1186/s13073-018-0551-4. View

Holtzman D, Morris J, Goate A . Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011; 3(77):77sr1. PMC: 3130546. DOI: 10.1126/scitranslmed.3002369. View

Pagani M, Nobili F, Morbelli S, Arnaldi D, Giuliani A, Oberg J . Early identification of MCI converting to AD: a FDG PET study. Eur J Nucl Med Mol Imaging. 2017; 44(12):2042-2052. DOI: 10.1007/s00259-017-3761-x. View

Zhao N, Ren Y, Yamazaki Y, Qiao W, Li F, Felton L . Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron. 2020; 106(5):727-742.e6. PMC: 7388065. DOI: 10.1016/j.neuron.2020.02.034. View

Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M . KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2020; 49(D1):D545-D551. PMC: 7779016. DOI: 10.1093/nar/gkaa970. View

Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367(9):795-804. PMC: 3474597. DOI: 10.1056/NEJMoa1202753. View

10.

Graham S, Chevallier O, Elliott C, Holscher C, Johnston J, McGuinness B . Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. PLoS One. 2015; 10(3):e0119452. PMC: 4372431. DOI: 10.1371/journal.pone.0119452. View

11.

John-Williams L, Blach C, Toledo J, Rotroff D, Kim S, Klavins K . Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Sci Data. 2017; 4:170140. PMC: 5644370. DOI: 10.1038/sdata.2017.140. View

12.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

13.

Coats M, Morris J . Antecedent biomarkers of Alzheimer's disease: the adult children study. J Geriatr Psychiatry Neurol. 2005; 18(4):242-4. DOI: 10.1177/0891988705281881. View

14.

Sheline Y, Snider B, Beer J, Seok D, Fagan A, Suckow R . Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial. Neurology. 2020; 95(19):e2658-e2665. PMC: 7713735. DOI: 10.1212/WNL.0000000000010725. View

15.

Gonzalez-Dominguez R, Sayago A, Fernandez-Recamales A . Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1071:75-92. DOI: 10.1016/j.jchromb.2017.02.008. View

16.

Del-Aguila J, Benitez B, Li Z, Dube U, Mihindukulasuriya K, Budde J . TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Mol Neurodegener. 2019; 14(1):18. PMC: 6505298. DOI: 10.1186/s13024-019-0319-3. View

17.

Zhao Y, Wu X, Li X, Jiang L, Gui X, Liu Y . TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron. 2018; 97(5):1023-1031.e7. PMC: 5889092. DOI: 10.1016/j.neuron.2018.01.031. View

18.

Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M . New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2018; 47(D1):D590-D595. PMC: 6324070. DOI: 10.1093/nar/gky962. View

19.

Bennett D, Schneider J, Arvanitakis Z, Wilson R . Overview and findings from the religious orders study. Curr Alzheimer Res. 2012; 9(6):628-45. PMC: 3409291. DOI: 10.2174/156720512801322573. View

20.

Yiannopoulou K, Papageorgiou S . Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis. 2020; 12:1179573520907397. PMC: 7050025. DOI: 10.1177/1179573520907397. View